Literature DB >> 29100957

Implications of farnesyltransferase and its inhibitors as a promising strategy for cancer therapy.

Sergey G Klochkov1, Margarita E Neganova1, Nagendra Sastry Yarla2, Madhukiran Parvathaneni3, Bechan Sharma4, Vadim V Tarasov5, George Barreto6, Sergey O Bachurin1, Ghulam Md Ashraf7, Gjumrakch Aliev8.   

Abstract

Ras proteins have been reported to play key role in oncologic diseases. Ras proteins are associated with cellular membranes for its carcinogenic activities through post-translational modifications, including farnesylation. Farnesyltransferase is responsible for a type of Ras membrane targeting, which leads to cancer origin and progression. Inhibitors of farnesyltransferase have been developed as novel anticancer agents. In this review, the role of farnesyltransferase in cancer progression and development has been discussed. Further, the current status of development of farnesyltransferase inhibitors for cancer prevention and treatment has also been reviewed.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cancer; Farnesyltransferase; Farnesyltransferase inhibitor; Ras protein; Therapy

Mesh:

Substances:

Year:  2017        PMID: 29100957     DOI: 10.1016/j.semcancer.2017.10.010

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  7 in total

1.  No room for statins in the quest for survival benefits in small cell lung cancer.

Authors:  Francesco Facchinetti; Marcello Tiseo
Journal:  Transl Lung Cancer Res       Date:  2018-04

Review 2.  Emerging therapeutic targets for neurofibromatosis type 1.

Authors:  James A Walker; Meena Upadhyaya
Journal:  Expert Opin Ther Targets       Date:  2018-05-07       Impact factor: 6.902

3.  Further assessments of ligase LplA-mediated modifications of proteins in vitro and in cellulo.

Authors:  Alicia Schirer; Anne Rouch; Estelle Marcheteau; Johann Stojko; Elodie Jeantet; Benjamin Fould; Gilles Ferry; Jean A Boutin
Journal:  Mol Biol Rep       Date:  2021-10-31       Impact factor: 2.316

Review 4.  Small GTPase RAS in multiple sclerosis - exploring the role of RAS GTPase in the etiology of multiple sclerosis.

Authors:  Samantha Messina
Journal:  Small GTPases       Date:  2018-09-18

Review 5.  Therapeutic Influence on Important Targets Associated with Chronic Inflammation and Oxidative Stress in Cancer Treatment.

Authors:  Margarita Neganova; Junqi Liu; Yulia Aleksandrova; Sergey Klochkov; Ruitai Fan
Journal:  Cancers (Basel)       Date:  2021-12-01       Impact factor: 6.639

6.  Lonafarnib Inhibits Farnesyltransferase via Suppressing ERK Signaling Pathway to Prevent Osteoclastogenesis in Titanium Particle-Induced Osteolysis.

Authors:  Linke Huang; Weiwei Chen; Linhua Wei; Yuangang Su; Jiamin Liang; Haoyu Lian; Hui Wang; Feng Long; Fan Yang; Shiyao Gao; Zhen Tan; Jiake Xu; Jinmin Zhao; Qian Liu
Journal:  Front Pharmacol       Date:  2022-03-01       Impact factor: 5.810

Review 7.  Structure, catalysis, and inhibition mechanism of prenyltransferase.

Authors:  Hsin-Yang Chang; Tien-Hsing Cheng; Andrew H-J Wang
Journal:  IUBMB Life       Date:  2020-11-27       Impact factor: 4.709

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.